Constipation from GLP-1 therapy may slow your overall digestive transit time, theoretically affecting medication absorption, though clinical studies show levothyroxine absorption remains adequate
Gate L, Majumdar RS, Lunk A, Tew KD
Most microbiome studies have focused on liraglutide, semaglutide, and dulaglutide, whereas evidence regarding short-acting agents such as exenatide remains comparatively limited
It received NICE approval for weight management (TA1026) in December 2024, with NHS access expanding through specialist weight management services
(Gross spending does not account for any rebates paid by drug manufacturers to pharmacy benefit managers, which would result in lower net Medicare spending.) Gross spending on Ozempic alone increased from $2.6 billion in 2021 to $4.6 billion in 2022, pushing it to 6th place among the top-selling drugs in Medicare Part D that year, up from 10th place the year before